Palvella Therapeutics (PVLA) Q2 FY26 earnings call

Palvella Therapeutics made significant strides in Q2 FY26, advancing its lead asset, QTORIN rapamycin, towards FDA approval for microcystic lymphatic malformations (MLM) with the first NDA module submitted. The company is also expanding its pipeline across multiple rare skin diseases, leveraging its QTORIN platform and a strong cash position to invest in pre-launch activities and clinical development. Management remains focused on bringing first-in-disease therapies to patients with high unmet needs.